Harpoon Therapeutics, Inc. (HARP)
| Market Cap | 343.78M |
| Revenue (ttm) | 23.15M |
| Net Income (ttm) | -99.08M |
| Shares Out | 31.58M |
| EPS (ttm) | -3.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $10.67 |
| Previous Close | $10.17 |
| Change ($) | 0.50 |
| Change (%) | 4.92% |
| Day's Open | 10.41 |
| Day's Range | 10.08 - 10.77 |
| Day's Volume | 1,283,384 |
| 52-Week Range | 9.87 - 25.24 |
Investors need to pay close attention to Harpoon Therapeutics (HARP) stock based on the movements in the options market lately.
Harpoon Therapeutics Inc (NASDAQ: HARP) provides updated interim data from the ongoing dose-escalation portion of the Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostat...
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provid...
Harpoon Therapeutics Inc (NASDAQ: HARP) has announced interim data from the ongoing dose-escalation portion of a Phase 1/2a trial evaluating HPN424 in patients with metastatic castration-resistant prost...
Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021 Management to host webcast and conference call to provide a pipeline update at 4 p.m....
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 13.95% and 32.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs
Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 22.41% and 52.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...
Provided positive update on its four TriTAC ® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...
Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
Underwriters Fully Exercise Option to Purchase Additional Shares Underwriters Fully Exercise Option to Purchase Additional Shares
Harpoon (HARP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced to...
HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development
Harpoon Therapeutics presents an opportunity in the cancer treatment space, and at the current levels, the stock is a good buy. HPN424, HARP's most advanced product, targets prostate cancer, which alone...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclin...
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today that th...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today report...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today ann...
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today repo...
Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board
SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...
Initiation of the clinical trial triggers $50 million milestone payment from AbbVie Initiation of the clinical trial triggers $50 million milestone payment from AbbVie
SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today ann...
The American Society of Clinical Oncology's annual meeting -- one of the most important healthcare industry gatherings of the year -- will happen without face-to-face contact.
Harpoon Therapeutics, Inc. (HARP) CEO Gerald McMahon on Q4 2019 Results - Earnings Call Transcript
As of late, it has definitely been a great time to be an investor in Harpoon Therapeutics, Inc. (HARP).
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year
HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...
Tag along on two of them -- but watch out for this biotech upstart, on which Wall Street might be a little early.
About HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the t... [Read more...]
| Industry Biotechnology | IPO Date Feb 8, 2019 |
| CEO Gerald McMahon | Employees 84 |
| Stock Exchange NASDAQ | Ticker Symbol HARP |
Financial Performance
In 2020, HARP's revenue was $17.44 million, an increase of 201.96% compared to the previous year's $5.78 million. Losses were -$49.91 million, -10.19% less than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for HARP stock is "Strong Buy." The 12-month stock price forecast is 29.30, which is an increase of 174.60% from the latest price.